BR112014014808A2 - combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação - Google Patents
combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparaçãoInfo
- Publication number
- BR112014014808A2 BR112014014808A2 BR112014014808A BR112014014808A BR112014014808A2 BR 112014014808 A2 BR112014014808 A2 BR 112014014808A2 BR 112014014808 A BR112014014808 A BR 112014014808A BR 112014014808 A BR112014014808 A BR 112014014808A BR 112014014808 A2 BR112014014808 A2 BR 112014014808A2
- Authority
- BR
- Brazil
- Prior art keywords
- ambroxol
- preparation
- rearrange
- ability
- compound
- Prior art date
Links
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 title abstract 8
- 229960005174 ambroxol Drugs 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 230000002132 lysosomal effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000000470 constituent Substances 0.000 abstract 8
- 108010045758 lysosomal proteins Proteins 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11010078 | 2011-12-22 | ||
| PCT/EP2012/005363 WO2013091897A1 (en) | 2011-12-22 | 2012-12-21 | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014014808A2 true BR112014014808A2 (pt) | 2018-09-25 |
Family
ID=47559375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014808A BR112014014808A2 (pt) | 2011-12-22 | 2012-12-21 | combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150258081A1 (https=) |
| EP (1) | EP2793872B1 (https=) |
| JP (2) | JP6320931B2 (https=) |
| KR (1) | KR102076585B1 (https=) |
| AU (2) | AU2012359165A1 (https=) |
| BR (1) | BR112014014808A2 (https=) |
| CA (1) | CA2860085A1 (https=) |
| ES (1) | ES2864774T3 (https=) |
| IL (1) | IL233173B (https=) |
| WO (1) | WO2013091897A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP6981961B2 (ja) * | 2015-07-30 | 2021-12-17 | ホライズン オルファン エルエルシー | フコシダーゼ阻害剤 |
| KR20250007693A (ko) | 2015-12-30 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| AU2017239641A1 (en) | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| US20190254992A1 (en) * | 2016-06-29 | 2019-08-22 | Hadasit Medical Research Services & Development Limited | Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations |
| WO2018089797A1 (en) * | 2016-11-14 | 2018-05-17 | Mingwu Wang | Formulations for the treatment of ocular surface diseases and related methods |
| CN110573492A (zh) * | 2017-04-25 | 2019-12-13 | 阿米库斯治疗学公司 | 用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物 |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11612619B2 (en) | 2018-11-01 | 2023-03-28 | National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government | Compostions and methods for enabling cholesterol catabolism in human cells |
| EP3884383B1 (en) * | 2018-12-21 | 2025-04-16 | Shenzhen Yinwang Intelligent Technologies Co., Ltd. | Data deterministic deliverable communication technology based on qos as a service |
| WO2020168294A1 (en) * | 2019-02-15 | 2020-08-20 | Lysosomal And Rare Disorders Research And Treatment Center, Llc | Methods and compositions for treating lysosomal storage disorders: ambroxol as treatment agent for mucopolysaccharidoses iii (sanfilippo syndrome) |
| EP3996696A1 (en) * | 2019-07-09 | 2022-05-18 | Genethon | Treatment of glycogen storage disease (gsd) |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US12544402B2 (en) | 2020-02-28 | 2026-02-10 | Repair Biotechnologies, Inc. | Targeted expression of microbial cholesterol catalysis genes reduces excess lipid |
| CN112773779B (zh) * | 2021-02-04 | 2022-08-16 | 上海交通大学医学院附属新华医院 | 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用 |
| CN114644572B (zh) * | 2022-03-22 | 2023-03-28 | 华南农业大学 | 一种溴己新半抗原、人工抗原、抗体及其制备方法和应用 |
| KR20260002803A (ko) * | 2023-05-02 | 2026-01-06 | 지위, 엘엘씨 | 치료적 사용을 위한 암브록솔의 변형된 형태 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19933148A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| EP2857036B1 (en) * | 2003-01-31 | 2016-12-21 | Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| PL2533050T6 (pl) * | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| JP5337405B2 (ja) * | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| CA2718182A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| EP2353403B1 (de) * | 2010-02-01 | 2012-07-11 | Symrise AG | Verwendung von 1-(2,4-Dihydroxy-phenyl)-3-(3-hydroxy-4-methoxy-phenyl)-propan-1-on |
-
2012
- 2012-12-21 KR KR1020147019849A patent/KR102076585B1/ko not_active Expired - Fee Related
- 2012-12-21 US US14/367,835 patent/US20150258081A1/en not_active Abandoned
- 2012-12-21 CA CA2860085A patent/CA2860085A1/en not_active Abandoned
- 2012-12-21 EP EP12815644.5A patent/EP2793872B1/en not_active Not-in-force
- 2012-12-21 AU AU2012359165A patent/AU2012359165A1/en not_active Abandoned
- 2012-12-21 ES ES12815644T patent/ES2864774T3/es active Active
- 2012-12-21 JP JP2014547767A patent/JP6320931B2/ja not_active Expired - Fee Related
- 2012-12-21 WO PCT/EP2012/005363 patent/WO2013091897A1/en not_active Ceased
- 2012-12-21 BR BR112014014808A patent/BR112014014808A2/pt not_active Application Discontinuation
-
2014
- 2014-06-16 IL IL233173A patent/IL233173B/en active IP Right Grant
-
2017
- 2017-12-22 AU AU2017279780A patent/AU2017279780B2/en not_active Ceased
- 2017-12-26 JP JP2017248953A patent/JP2018076353A/ja active Pending
-
2021
- 2021-04-05 US US17/222,254 patent/US20210228560A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210228560A1 (en) | 2021-07-29 |
| AU2012359165A1 (en) | 2014-07-10 |
| EP2793872B1 (en) | 2021-03-10 |
| AU2017279780A1 (en) | 2018-01-25 |
| ES2864774T3 (es) | 2021-10-14 |
| IL233173A0 (en) | 2014-07-31 |
| KR20140107481A (ko) | 2014-09-04 |
| AU2017279780B2 (en) | 2019-10-03 |
| EP2793872A1 (en) | 2014-10-29 |
| KR102076585B1 (ko) | 2020-02-12 |
| WO2013091897A8 (en) | 2014-10-09 |
| JP2015502964A (ja) | 2015-01-29 |
| IL233173B (en) | 2020-10-29 |
| CA2860085A1 (en) | 2013-06-27 |
| JP2018076353A (ja) | 2018-05-17 |
| JP6320931B2 (ja) | 2018-05-09 |
| WO2013091897A1 (en) | 2013-06-27 |
| US20150258081A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014808A2 (pt) | combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação | |
| BR112012018386A2 (pt) | "inibidores isoindolinona de fosfatidilinositol 3-quinase" | |
| BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| CR9949A (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
| BR112014017840A8 (pt) | Compostos terapeuticamente ativos, sua composição farmacêutica e seu uso | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| BR112014015845A2 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| BR112013031402A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| BR112014004651A2 (pt) | composto de pirazol e uso farmacêutico do mesmo | |
| IN2014CN01930A (https=) | ||
| PH12014501176A1 (en) | Anticoagulant reversal agents | |
| BR112014007223A2 (pt) | derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos | |
| BR112012022109A2 (pt) | derivados de aminoindanos, seu preparo e sua aplicação em produtos terapêuticos | |
| BR112014014877A2 (pt) | derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos | |
| BR112012015984A2 (pt) | composição para melhorar a função cerebral, e, polipeptídeo | |
| BR112015001207A2 (pt) | derivados de carbamato/ureia | |
| NZ631105A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| BR112013018287A2 (pt) | derivados monoterpenos de chalcona ou de diidrochalcona e sua utilização como agentes de despigmentação | |
| HK1223632A1 (zh) | 靶向的酶化合物及其用途 | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| BR112014029597A2 (pt) | compostos de cromano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: CENTOGENE IP GMBH (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |